February 21, 2024
1 min watch
Save
VIDEO: Tildrakizumab shows ‘increasing efficacy and improvement’ for psoriasis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor tildrakizumab from the Maui Derm 2024 meeting.
Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed a phase 4 study evaluating the real-world effectiveness of tildrakizumab (Ilumya, Sun Dermatology) over 64 weeks.
“What was found is starting right at the first dose and going all the way to the end, there was increasing efficacy and improvement in patients throughout, suggesting that what we’ve seen in the Phase 3 trials is really being mirrored in a real-world population,” Chovatiya said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Chovatiya reports being an advisor, consultant, speaker and/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi and UCB.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.